The drugmaker said it agreed to pay RAPT Therapeutics shareholders $58 per share, with $1.9 billion upfront investment in cash.
Source link
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
Date:
More like thisRelated
The Lobos enter the 2026 season with a stacked quarterback room
ALBUQUERQUE, N.M. (KRQE) – In his second season at...
What is enterprise marketing automation? Features, platforms, and best practices
Enterprise marketing automation is how large organizations scale personalized...
Allianz Posts Lower Net Profit Amid Portfolio Reshuffle
Europe’s largest insurer by market capitalization booked an 11%...